Autonomix Medical, Inc. (AMIX)
| Market Cap | 5.17M -22.4% |
| Revenue (ttm) | n/a |
| Net Income | -16.11M |
| EPS | -36.37 |
| Shares Out | 971.04K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 314,745 |
| Open | 5.37 |
| Previous Close | 5.63 |
| Day's Range | 5.08 - 5.61 |
| 52-Week Range | 2.44 - 32.55 |
| Beta | -1.15 |
| Analysts | Buy |
| Price Target | 58.80 (+1,005.26%) |
| Earnings Date | Aug 13, 2026 |
About AMIX
Autonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders of nervous system. The company’s technology platform includes a catheter-based system incorporating microchip-enabled sensing architecture designed to detect low-amplitude neural signals from within the vascular system. It develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related disorders. Autonomix Med... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for AMIX stock is "Buy." The 12-month stock price target is $58.8, which is an increase of 1,005.26% from the latest price.
News
Autonomix announces new U.S. patent
Autonomix (AMIX) announced the issuance of U.S. Patent No. 12,714,780 by the United States Patent and Trademark Office, or USPTO, titled “Systems and Methods for Regulating Organ and/or Tumor Growth…
Autonomix Medical Expands Intellectual Property Portfolio with New U.S. Patent Covering Feedback-Guided Precision Neuromodulation and Targeted Therapy Delivery
New patent broadens protection around systems integrating real-time physiological feedback, sensing and imaging with controlled therapeutic delivery, including neural ablation approaches for cancer pa...
Autonomix Medical Enters into $4.9 Million Warrant Inducement Priced at a Premium to Market Under Nasdaq Rules
THE WOODLANDS, TX, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted tre...
Autonomix completes GLP preclinical study, plans FDA submission
Autonomix (AMIX) Medical announced the successful completion of its Good Laboratory Practice preclinical study, a significant regulatory milestone supporting the company’s submission to the FDA. The s...
Autonomix Medical Quarterly report: Q1 2027
Autonomix Medical has published its Q1 2027 quarterly earnings report on August 13, 2026.
Autonomix Medical Completes Good Laboratory Practice (GLP) Preclinical Study, Marking Key Step Toward FDA Submission
Final histology and laboratory analyses support the study's safety and performance objectives THE WOODLANDS, TX, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” o...
Autonomix Medical Congratulates Co-Founder & Chief Medical Officer Dr. Robert Schwartz on Receiving Prestigious 2026 Cardiovascular Tech Forum Lifetime Achievement Award
Recognition honors one of the medical technology industry's most influential innovators, whose career has helped shape modern cardiovascular care
Autonomix Medical Inc trading resumes
09:41 EDT Autonomix (AMIX) Medical Inc trading resumes
Autonomix Medical Inc trading halted, volatility trading pause
09:31 EDT Autonomix (AMIX) Medical Inc trading halted, volatility trading pause
Why Is Penny Stock Autonomix Medical (AMIX) Up Today?
Autonomix Medical stock took off after the company revealed a new patent in the U.S.
Autonomix issued U.S. patent for nerve sensing, mapping
Autonomix (AMIX) announced the issuance of U.S. Patent No. 12,433,670, titled “Systems and Methods for Treating Cancer and/or Augmenting Organ Function.” The patent expands the company’s intellectual ...
Autonomix Medical Expands Precision Neuromodulation Platform with Broad New U.S. Patent Supporting Nerve Sensing, Mapping and Targeted Therapy
Patent expands protection for technology designed to sense, map and selectively target nerves associated with tumors and cancer-related pain
Autonomix files to sell 857,462 shares of common stock for holders
17:03 EDT Autonomix (AMIX) files to sell 857,462 shares of common stock for holders
Autonomix Medical Registration statement: Registration filing
Autonomix Medical filed a registration statement on July 28, 2026, providing details about a securities offering with the SEC.
Autonomix Medical Demonstrates Renal Nerve Sensing and Neural Activity Change in Preclinical Study
Data demonstrate the ability to detect, localize and confirm changes in renal neural activity, supporting continued development of physiology-guided renal denervation
Autonomix secures new U.S. patent for autonomic nervous system technologies
Autonomix (AMIX) announced the issuance of U.S. Patent No. 12,471,776, titled “ANS Assessment Systems, Kits, and Methods,” further strengthening the company’s intellectual property portfolio supportin...
Autonomix Medical Secures New U.S. Patent Strengthening Next-Generation Precision Neuromodulation Platform
Patent Broadens Intellectual Property Protecting Advanced Autonomic Nervous System Assessment Technologies Designed to Enhance Patient Selection, Treatment Precision and Future Clinical Applications T...
Autonomix granted U.S. patent for overactive bladder diagnosis
Autonomix (AMIX) announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,611,134, titled “Devices, Systems, and Methods for Diagnosis and Treatment of Overactive Bla...
Autonomix Medical Granted U.S. Patent for Overactive Bladder Diagnosis and Treatment Platform
Newly Issued Patent Expands Company's Neural Sensing Technology Platform into Large Urology Market Affecting Approximately 37 Million Americans THE WOODLANDS, TX, July 15, 2026 (GLOBE NEWSWIRE) -- Aut...
Autonomix enters into $2.6M warrant inducement priced at $6.00
Autonomix (AMIX) Medica announced it has entered into a warrant inducement agreement with an investor for the immediate exercise of certain outstanding warrants that the Company issued on November 19,...
Autonomix Medical Enters into $2.6 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules
THE WOODLANDS, TX, July 13, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted tre...
Autonomix granted Canadian patent for neural sensing
Autonomix (AMIX) announced that it has been granted Canadian Patent No. 3,158,197, titled “Endoscopic Sympathectomy Systems and Methods.” The company’s intellectual property portfolio now includes 112...
Autonomix Medical Strengthens Global Intellectual Property Position with New Neural Sensing Patent Grant
IP portfolio reflects Autonomix's neural sensing leadership in multi-billion-dollar denervation market Technical highlights on newly issued patent include real-time nerve monitoring and diagnostic eva...
Autonomix Medical Slides: Investor presentation
Autonomix Medical has posted slides in relation to its latest quarterly earnings report, which was published on July 7, 2026.
Autonomix Medical Inc trading halted, news pending
19:50 EDT Autonomix (AMIX) Medical Inc trading halted, news pending